Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University Of Colorado Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI greater than 40
- No known history of allergy to cephalosporins
- Scheduled for elective gastric bypass or laparoscopic Roux-en-y gastric bypass procedures
- Able to read and understand English
Exclusion Criteria:
- Patients <18 years of age or >89 Years of age
- Pregnant women, prisoners and decisionally challenged subjects will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control group
Standard dose group (2 g intravenous (IV) cefazolin dose for patients <120 kg, and 3 g IV cefazolin for patients >120 kg)
|
The standard dose of Cefazolin will be administered intravenously.
|
|
Experimental: Treatment group
Weight-based dose group (30 mg/kg cefazolin IV)
|
The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of the Pharmacokinetics of Cefazolin in the Morbidly Obese
Time Frame: Before cefazolin admin., then at 10, 30, 60, 120, 180 minutes after injection and at wound closure.
|
Since the goal of perioperative antimicrobial prophylaxis is to achieve free (unbound) serum and tissue drug levels that exceed the MIC for likely pathogens across the duration of the surgical procedure, and since redosing of cefazolin is recommended every 3-4 hours, PK/PD performance of cefazolin over that time frame will be analyzed.
For the purposes of this study, pharmacodynamic targets are defined as fT>MIC (time during which free drug concentrations exceed pathogen MICs) of 100% over periods of up to 4 hours in duration.
The PK/PD probability of target attainment (PTA) for pharmacodynamic goals and the cumulative fraction of response (CFR) for both cefazolin regimens will be compared.
A PTA of ≥90% and a CFR of ≥ 90% for a dosage regimen (i.e., predicted to meet pharmacodynamic targets in ≥ 90% of the total bacterial population across the full range of MICs) are considered optimum.
|
Before cefazolin admin., then at 10, 30, 60, 120, 180 minutes after injection and at wound closure.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of surgical site infection
Time Frame: Within 1 month postoperatively
|
The incidence of surgical site infection will be monitored and compared.
|
Within 1 month postoperatively
|
|
Hospital length of stay
Time Frame: Hospital discharge
|
The length of time the subject is hospitalized will be monitored and compared.
|
Hospital discharge
|
|
Hospital readmission
Time Frame: Witihn 1 month after hospital discharge
|
Hospital readmission within 1 month postoperatively.
|
Witihn 1 month after hospital discharge
|
|
Incidence of adverse outcomes
Time Frame: Within 1 month postoperatively
|
Adverse outcomes in these patients will be monitored and compared.
|
Within 1 month postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pierre Moine, M.D., University of Colorado, Denver
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 12-1653
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.